Related Experiment Video
Updated: Jan 5, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Renin-angiotensin system gene polymorphisms and colorectal cancer risk: a meta-analysis
1International Healthcare Center, Sir Run Run Shaw Hospital, China.
Objective:
The renin-angiotensin system gene has been implicated in the progression of colorectal cancer. Nevertheless, the details of that role remain controversial. We performed a meta-analysis to investigate the correlation between renin-angiotensin system gene polymorphisms and colorectal cancer.
Methods:
We retrieved relevant studies from PubMed and Embase. Subsequently, fixed or random-effects models were used to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs).
Results:
We identified six studies of the angiotensin-converting enzyme insertion/deletion (I/D) polymorphism, and two studies of the angiotensinogen M235T polymorphism. The angiotensin-converting enzyme I/D polymorphism did not significantly correlate with colorectal cancer risk in the total population (DD vs. II: OR 0.77, 95% CI 0.39-1.50; DI vs. II: OR 1.05, 95% CI 0.85-1.30; dominant model: OR 0.94, 95% CI 0.68-1.31; recessive model: OR 1.01, 95% CI 0.80-1.27). Similarly, the angiotensinogen M235T polymorphism was not associated with colorectal cancer risk (TT vs. MM: OR 1.38, 95% CI 0.52-3.67; TM vs. MM: OR 1.19, 95% CI 0.96-1.47; dominant model: OR 1.28, 95% CI 0.77-2.14; recessive model: OR 1.17, 95% CI 0.53-2.59).
Conclusion:
Our findings suggest that the angiotensin-converting enzyme I/D and angiotensinogen M235T polymorphisms are unlikely to correlate with colorectal cancer.
More Related Videos
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers

